Product Description
Aceclidine has been marketed in Europe but has not been used clinically in the United States. It is used in the treatment of open-angle glaucoma and is a parasympathomimetic agent.
Mechanisms of Action: mAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: *
Approval Status: Approved
Approved Countries: Germany | Greece | Italy | Peru | Portugal
Approved Indications: None
Known Adverse Events: None
Company: LENZ Therapeutics
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
- PDUFA date: August 8, 2025, assigned by the FDA for LNZ100 from Lenz Therapeutics, an aceclidine-based eye drop for presbyopia.
Highest Development Phases
Phase 3: Miosis|Presbyopia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06045299 |
JX07001 | P3 |
Completed |
Presbyopia|Miosis |
2024-08-19 |
14% |
2025-03-04 |
Primary Endpoints |
CTR20240460 |
CTR20240460 | P1 |
Completed |
Presbyopia |
2024-04-10 |
12% |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
NCT05936489 |
NCT05936489 | P1 |
Completed |
Presbyopia |
2023-10-03 |
23% |
2023-10-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06270030 |
JX07002 | P1 |
Completed |
Presbyopia |
2024-04-10 |
12% |
2025-08-27 |
Primary Endpoints |
NCT05753189 |
Safety Study | P3 |
Completed |
Presbyopia|Miosis |
2024-02-09 |
13% |
2024-12-19 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT05656027 |
CLARITY | P3 |
Completed |
Miosis|Presbyopia |
2023-12-15 |
13% |
2024-02-01 |
Primary Endpoints |
NCT05728944 |
CLARITY | P3 |
Completed |
Miosis|Presbyopia |
2023-12-14 |
17% |
2024-02-01 |
Primary Endpoints|Study Completion Date |